Establish a global Post-Viral Precision Medicine Initiative (PPMI) combining three tightly integrated components: (1) Unified International Long COVID Cohorts: Fund and harmonize 20 existing Long COVID cohorts across 15 countries into a single 100,000-person international research cohort with standardized phenotyping (symptom batteries, functional capacity, biomarker collection, and serial follow-up).

Use federated data governance to preserve patient privacy while enabling cross-national analysis. (2) Biomarker Discovery Engine: Fund 50 biomarker discovery projects across the 6 leading mechanistic hypotheses (viral persistence, autoimmunity, microclots, dysbiosis, mitochondrial dysfunction, neuroinflammation) using the cohort data and tissue samples.

Structure as a 'winner-take-all' competition where leading mechanistic hypotheses receive scaled-up funding for validation and therapeutic development.

(3) Decentralized Treatment Networks: Establish Post-Viral Care Centers in 100 major cities that provide integrated diagnostic protocols (multi-system biomarker testing, functional imaging, immunophenotyping) and mechanism-based experimental therapies (anticoagulation for microclot hypothesis, immunotherapy trials for autoimmunity hypothesis, probiotics + dietary interventions for dysbiosis).

Networked telemedicine enables access from underserved rural areas.